Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
579.20 | 14,334 Cr | -397.61 | 4.81 | 0.17 | 8.48 | 6.61 | -0.59 | ||
1189.20 | 7,971 Cr | 25.20 | 2.72 | 0.63 | 9.98 | 11.61 | 4.85 | ||
683.30 | 6,747 Cr | 48.00 | 7.49 | 0.00 | 15.26 | 15.10 | 8.55 | ||
911.80 | 2,867 Cr | 28.51 | 2.22 | 0.66 | 8.41 | 11.07 | 4.56 | ||
878.10 | 2,009 Cr | 11.91 | 1.86 | 1.02 | 14.54 | 19.08 | 13.77 | ||
72.86 | 1,514 Cr | -48.28 | 1.94 | 0.00 | 1.90 | 5.32 | -2.06 | ||
727.45 | 1,447 Cr | 17.51 | 2.08 | 0.28 | 12.73 | 16.31 | 9.66 | ||
| Median: 7 Co. | — | 727.45 | 2,867 Cr | 17.51 | 2.22 | 0.28 | 9.98 | 11.61 | 4.85 |
India Glycols Limited (IGL) is an integrated bio-based chemicals and consumer alcohol manufacturer with businesses in Bio-based Specialties & Performance Chemicals (BSPC), Bio-Fuel (ethanol/ENA), Potable Spirits (IMFL and country liquor) and Ennature Biopharma (plant-based APIs and nutraceuticals), operating three major manufacturing hubs at Kashipur, Gorakhpur and Dehradun with global exports and multiple strategic JVs.
Q3FY26 and 9MFY26 delivered record net turnover and EBITDA for India Glycols, with 9M revenue rising 11.4% and EBITDA up 28.9% (EBITDA margin 15.0%), and Q3 revenue up 13% with EBITDA up 36.1% as management cites realization of operational actions and high‑margin mix shift driving margin expansion across BSPC and Biofuel segments.
IGL materially reduced gross debt by ₹582 crore (₹467 crore raised via preferential allotment plus internal accruals) and is executing swaps of high-cost borrowings; management expects a visible reduction in interest cost in Q4 FY26 and is targeting further prepayments and lower cost of funds post-demerger.
The company is executing a major restructuring: a sanctioned demerger effective 1 April 2026 to create IGL (chemicals), IGL Spirits Limited (spirits and biofuels) and Ennature Bio Pharma Limited, intended to sharpen management focus, unlock value and allow each entity to access investor and regulatory ecosystems suited to its industry.
Strategic commercial moves underpin future growth: premiumisation and geographic expansion in Potable Spirits (Amrut partnership, CSD entry, Kerala rollout), rapid ethanol scale supporting biofuels and internal feedstock for chemicals, and an expanding BSPC pipeline including bio-based amines sold to marquee customers such as L'Oreal.
Beverages
Breweries & Distilleries
7,971 Cr
High Risk
25.2
52.8
0.6
2.7
1,222.85
793.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
India Glycols Ltd (INDIAGLYCO) is currently trading at 1,168.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
India Glycols Limited (IGL) is an integrated bio-based chemicals and consumer alcohol manufacturer with businesses in Bio-based Specialties & Performance Chemicals (BSPC), Bio-Fuel (ethanol/ENA), Potable Spirits (IMFL and country liquor) and Ennature Biopharma (plant-based APIs and nutraceuticals), operating three major manufacturing hubs at Kashipur, Gorakhpur and Dehradun with global exports and multiple strategic JVs. Q3FY26 and 9MFY26 delivered record net turnover and EBITDA for India Glycols, with 9M revenue rising 11.4% and EBITDA up 28.9% (EBITDA margin 15.0%), and Q3 revenue up 13% with EBITDA up 36.1% as management cites realization of operational actions and high‑margin mix shift driving margin expansion across BSPC and Biofuel segments. IGL materially reduced gross debt by ₹582 crore (₹467 crore raised via preferential allotment plus internal accruals) and is executing swaps of high-cost borrowings; management expects a visible reduction in interest cost in Q4 FY26 and is targeting further prepayments and lower cost of funds post-demerger. The company is executing a major restructuring: a sanctioned demerger effective 1 April 2026 to create IGL (chemicals), IGL Spirits Limited (spirits and biofuels) and Ennature Bio Pharma Limited, intended to sharpen management focus, unlock value and allow each entity to access investor and regulatory ecosystems suited to its industry. Strategic commercial moves underpin future growth: premiumisation and geographic expansion in Potable Spirits (Amrut partnership, CSD entry, Kerala rollout), rapid ethanol scale supporting biofuels and internal feedstock for chemicals, and an expanding BSPC pipeline including bio-based amines sold to marquee customers such as L'Oreal.
Over the past 52 weeks, India Glycols Ltd has traded between a low of ₹793.95 and a high of ₹1,222.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
India Glycols Ltd has a market capitalization of approximately 7,970.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
India Glycols Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.20 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7,970.82 Cr, India Glycols Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
India Glycols Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of India Glycols Ltd is 25.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The NCLT Allahabad Bench sanctioned the scheme on July 17, 2026. India Glycols said it received the certified true copy on August 20, 2026.
The Allahabad Bench of the NCLT sanctioned the demerger scheme on July 17, 2026.
The NCLT Allahabad Bench sanctioned India Glycols’ scheme of arrangement to demerge its biopharma and spirits-biofuel undertakings into Ennature Bio Pharma and IGL Spirits.
Consolidated net profit after tax (PAT) rose 32.2% year-on-year to ₹96.8 crore for the quarter ended June 30, 2026.
Bearish
4
Neutral
6
Bullish
4
Bearish
5
Neutral
6
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Bearish
4
Neutral
6
Bullish
4
Bearish
4
Neutral
6
Bullish
4
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Change in Directors/KMP
India Glycols informs exchanges of a material update from IGL Spirits: board approved appointment of U.S. Bhartia as Chairman & MD and six additional directors (including independent directors) effective 2026-08-21, subject to shareholder approval.
Change in Directors/KMP
India Glycols informs exchanges that IGL Spirits' board approved appointment of U.S. Bhartia as Chairman & MD and several additional/independent directors w.e.f. 2026-08-21, subject to shareholder approval, per observation letters.
Change in Directors/KMP
India Glycols reports Ennature Bio Pharma has appointed Ms. Pragya Bhartia Barwale as Managing Director (KMP) w.e.f. 21-08-2026 and several additional and independent directors; disclosures filed with exchanges.
Change in Directors/KMP
India Glycols files material update: Ennature Bio Pharma's board on 21-08-2026 appointed Ms Pragya Bhartia Barwale as Managing Director and several additional/independent directors, subject to shareholder approval, per stock-exchange observation letters.
Scheme of Arrangement
India Glycols Ltd fixed Effective Date as 2026-09-01 and Record Date as 2026-09-02 for the NCLT-sanctioned Scheme of Arrangement; share entitlements: Ennature Bio Pharma (1 share per 3 IGL shares) and IGL Spirits (1 per 1).
Scheme of Arrangement
India Glycols Ltd fixed Effective Date as 2026-09-01 and Record Date as 2026-09-02 for its NCLT‑sanctioned scheme; Ennature Bio Pharma to allot 1 share per 3 and IGL Spirits 1 share per 1 held.
